Defense Secretary Pete Hegseth's reported push for broad low-testosterone screening across the Army is igniting concern in both medical and defense circles, with early estimates indicating that as many as one in four soldiers could be flagged. The figure, if borne out, would place the policy at the center of a larger debate over how the Pentagon defines readiness, masculinity, and medical fitness in an era of tightening recruitment standards and rising scrutiny of military health policy.
Screening Under Scrutiny
Medical experts have explicitly warned against blanket testosterone testing, arguing that hormone levels vary widely by age, time of day, stress, sleep, illness, and medication use. In practice, a mass-screening program could identify large numbers of service members whose readings fall below a statistical threshold without necessarily indicating a clinically meaningful disorder. That distinction matters: low laboratory values do not automatically translate into impaired performance, and treatment decisions based on a single test can be medically unsound.
The concern is not merely academic. If the Army were to screen broadly and treat the results as a readiness marker, it could trigger a cascade of follow-up testing, referrals, and potentially unnecessary prescriptions. That would impose administrative burdens on military medical systems already stretched by operational demands, while also risking the stigmatization of troops who may be healthy, deployable, and fully capable of performing their duties.
Readiness Versus Evidence
The reported policy direction reflects a broader trend in which military leaders seek simple physiological metrics to explain complex readiness challenges. But experts say testosterone is an especially poor candidate for a blanket force-wide screen because the science does not support using it as a universal proxy for strength, resilience, or combat effectiveness. Low levels can be associated with fatigue, reduced libido, or other symptoms, yet many individuals with borderline results are asymptomatic and require no intervention.
That is why major medical guidance generally favors symptom-driven evaluation rather than universal screening. Physicians typically recommend testing only when a patient presents with persistent symptoms and after other causes have been considered. In the military context, that approach is even more important because service members operate under unique physical and psychological stressors that can temporarily affect hormone levels without indicating chronic disease.
A large-scale screening program could also create perverse incentives. Troops worried about being labeled unfit may underreport symptoms, avoid medical visits, or seek outside treatment without proper oversight. Commanders, meanwhile, could face pressure to interpret a lab result as a proxy for performance, even when no evidence supports that conclusion. The result would be a policy that looks decisive on paper but may undermine trust in military medicine in practice.
Policy And Political Stakes
The issue has broader implications for the Pentagon's management culture. Hegseth has positioned himself as a hardline advocate for force readiness and discipline, but the proposed screening approach risks being seen as more ideological than evidence-based. In a military environment where recruitment, retention, and medical trust are already under strain, a policy perceived as medically dubious could deepen skepticism among service members and clinicians alike.
It also raises questions about how far defense leadership should go in using health data to shape personnel policy. The Army has long relied on medical standards to determine deployability, but those standards are usually grounded in functional impairment, not broad population screening. If the Pentagon moves ahead with a low-testosterone initiative, it may face criticism that it is substituting a politically resonant narrative for sound clinical judgment.
For now, the reported estimate that up to 25 percent of the Army could be flagged underscores the scale of the potential fallout. A policy intended to strengthen readiness could instead expose the force to unnecessary medicalization, administrative overload, and reputational damage. The central question is not whether testosterone matters in individual cases; it is whether the Pentagon should treat a complex medical issue as a mass-screening problem. On that point, the medical consensus appears to be moving in the opposite direction.